Fetal outcomes with and without the use of sugammadex in pregnant patients undergoing non-obstetric surgery: a multicenter retrospective study. (February 2023)

• Record Type: Journal Article
• Authors: Noguchi, S.; Iwasaki, H.; Shiko, Y.; Kawasaki, Y.; Ishida, Y.; Shinomiya, S.; Ono Uokawa, R.; Mazda, Y.
• Is Part Of: International journal of obstetric anesthesia. Volume 53(2023)
• Publication Date: 2023-02
• Subjects: Fetal development -- Neostigmine -- Non-obstetric surgery -- Pregnancy -- Sugammadex; Obstetrics -- Periodicals; Anesthesia -- Periodicals; Anesthésie en obstétrique -- Périodiques; Anesthesia; Obstetrics; Electronic journals; Periodicals; 617.9682
• DOI: 10.1016/j.ijoa.2022.103620
• Languages: English
• ISSNs: 0959-289X

Abstract

Highlights: Seventy-three pregnant women received sugammadex in non-obstetric surgery. Sugammadex was not associated with miscarriage or preterm labor within four weeks. Missing data may have obscured potential adverse outcomes from sugammadex exposure. The findings do not exclude sugammadex-related adverse pregnancy outcomes. Abstract: Background: The influence of sugammadex exposure during pregnancy on progesterone withdrawal and miscarriage is unknown. We aimed to compare the fetal outcomes in pregnant patients who had undergone non-obstetric surgery with and without sugammadex. Methods: We retrospectively reviewed the medical charts of pregnant women who underwent non-obstetric surgery at three tertiary perinatal care centers in Japan from January 2013 to December 2020. The women were divided into those who received general anesthesia with sugammadex (GA with SGX) and those who received general anesthesia without sugammadex (GA without SGX). We compared miscarriages and preterm births within four weeks after surgery. Results: Among the 124 women, 73 and 51 were included in the GA with SGX and GA without SGX groups, respectively. The two groups showed no differences in the rate of miscarriages or preterm births (3.0 % vs 4.3 %; odds ratio 1.42, 95 % confidence interval 0.19 to 10.47; P = 1.00). The SGX and no SGX groups were missing outcomes for 8.2 % and 7.8 % of cases, respectively. Conclusions: Having GA with SGX or GA without SGX did not result in different rates of miscarriage or preterm birth within four weeks after the procedure. These findings do not exclude a potential association between sugammadex exposure during pregnancy and adverse pregnancy outcomes. Missing data may have obscured possible adverse outcomes from sugammadex exposure.